Making the compound Amanitin available for cancer therapies

Our mission is to research and develop drugs for cancer patients to provide them
with a targeted, tailor-made and highly effective treatment option

ADC Drug Development

We use the active ingredient Amanitin from the death cap mushroom for cancer therapies by researching, producing and clinically developing so-called Antibody Amanitin Conjugates.

ATACs belong to the class of Antibody Drug Conjugates (ADCs), which combine the high affinity and specificity of antibodies with the efficacy of small toxic molecules to fight cancer.


Heidelberg Pharma reports on the results of the Annual General Meeting 2023
25 May 2023
PR: Heidelberg Pharma appoints Chief Financial Officer
05 May 2023
PR: Heidelberg Pharma AG: Interim Management Statement on the First Three Months of 2023
13 April 2023
PR: Heidelberg Pharma Presents New Preclinical Data from its Proprietary ATAC Technology Platform at AACR Annual Meeting 2023
04 April 2023

Meet us

Stifel European Healthcare Summit
28 June 2023
ICML International Conference on Malignant Lymphoma
13 June 2023
EHA2023 Hybrid Congress
08 June 2023
BIO International Convention
05 June 2023

Partner Informationen

Telix’s ZIRCON Phase III Kidney Cancer Imaging Study Presented in “Game Changing” Session at EAU
14 March, 2023
Read more
RedHill Announces Publication of Positive Phase 2 Study Results with Once-Daily Oral RHB-107 in Non-Hospitalized COVID-19
3 January 2023
Read more

© Heidelberg Pharma AG. All rights reserved.